Healthcare Business

Wall St Bull statue

Will Biogen Earnings Interrupt the Biotech Bull Market?

Biogen Inc. (NASDAQ: BIIB) reported its first-quarter financials before the markets opened Friday. The biotech giant had $3.82 in earnings per share (EPS) on $2.55 billion in revenue, versus Thomson ...
Read Full Story »

GW Pharma Gets Big Analyst Upgrade Into Cannabinoid FDA Orphan Drug Designation

GW Pharmaceuticals PLC (NASDAQ: GWPH) was recently listed as the top medical marijuana stock for National Weed Day, but other things are going on here besides weird holidays. GW recently ...
Read Full Story »
generic drugs

Amgen Earnings Point to More Froth in the Biotech Sector

Amgen Corp. (NASDAQ: AMGN) reported first-quarter 2015 earnings Tuesday afternoon after equity markets had closed. The biotech firm posted adjusted earnings per share (EPS) of $2.48 on revenues of $5.03 ...
Read Full Story »

Will Amgen Earnings Shape Biotech for the Rest of 2015?

After markets close on Tuesday, Amgen Inc. (NASDAQ: AMGN) is scheduled to announce its first-quarter results. Among biotech companies Amgen is the second-largest measured by market cap, trailing only Gilead ...
Read Full Story »

Can La Jolla Pharma Shares Really Double?

Health care is still going strong in April, and biotech and emerging pharmaceutical stocks still have huge gains so far in 2015. La Jolla Pharmaceutical Co. (NASDAQ: LJPC) has seen ...
Read Full Story »
Prescription drugs

Why Teva Really Wants to Acquire Mylan

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) has just approached Mylan N.V. (NASDAQ: MYL) with a public takeover bid valued at $82 per share in cash and stock. The offering would consist ...
Read Full Story »

BioCryst Upgrade Almost Looks Misunderstood

The most recent analyst call by Merrill Lynch for BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) may be very misunderstood for what it is. The brokerage firm upgraded BioCryst to Neutral and ...
Read Full Story »

Genetic Technologies Drives Ahead in the Fight Against Cancer

Genetic Technologies Limited (NASDAQ: GENE) has been making large strides in the area of women’s health recently with the opening of more centers that utilize the BREVAGenplus. Ultimately this will ...
Read Full Story »

Is Ampio at Risk of Imploding?

Companies in the biotech and pharmaceuticals field are generally riskier than other companies because a single failed study could make or break the company, similar to what happened with Ampio ...
Read Full Story »
marijuana leaf

Is GW Pharmaceuticals the Perfect Cannabis Stock on National Weed Day?

With Monday, April 20, being National Weed Day (a 4:20 takeoff), 24/7 Wall St. wondered which marijuana stocks were either the best in class or had the most upside. The ...
Read Full Story »

3 Big Pharmaceutical Stocks Will Have Rising Q1 Earnings

One thing investors look for in an aging bull market, especially one trading near all-time highs, is rising earnings. That is the only way to justify multiples that creep up ...
Read Full Story »
Biotechnology word cloud

4 Biotech and Pharma Stocks Projected to Rise 50% to 100%

Biotech has been one hot sector again in 2015. Two key biotech exchange traded funds are up 20% or so on average year-to-date. 247 Wall St. could not help but ...
Read Full Story »

5 Big Biotechs Not Keeping Up at All With Hot Biotech Sector in 2015

The health care sector and biotech in particular have been on fire so far in 2015, but some biotech stocks in the group just are not carrying their weight. The ...
Read Full Story »

Akebia Hits New Low After Pricing Secondary Offering

Akebia Therapeutics Inc. (NASDAQ: AKBA) announced the pricing for its secondary offering Thursday evening. A total of 7.27 million shares of common stock were registered for the offering at a ...
Read Full Story »
health care

Are Billions About to Be Made in Cosmetic Dermatology by 3 Companies?

While few people may want to admit it, but more and more cosmetic surgery and treatments are being done every year. While non-surgical procedures like botox treatments are huge, so ...
Read Full Story »